VG Life Sciences, Inc., a biotechnology company developing therapies for cancer, autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office will issue Patent No. 9073985 covering VGLS’ combination therapy for treating drug-resistant cancer by combining an autophagy inhibitor with a chemotherapy drug.

View the original here:
VG Life Sciences receives U.S. patent for combination cancer therapy

Scroll to Top